Celecoxib

Name: Celecoxib
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (47 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

47 publications

CAS No. 169590-42-5

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib has been cited by 47 publications

J Clin Invest, 2020, 26;132417

PubMed: 32452837 ( click the link to review the publication )

Cell Death Differ, 2020, 20

PubMed: 32433558 ( click the link to review the publication )

Nanotoxicology, 2020, 14(2):162-180

PubMed: 31703536 ( click the link to review the publication )

Cells, 2020, 14;9(5):E1222

PubMed: 32423044 ( click the link to review the publication )

Neoplasia, 2020, 22(11):576-589

PubMed: 32980776 ( click the link to review the publication )

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Brain Res, 2020, 20;1740:146846

PubMed: 32325074 ( click the link to review the publication )

AAPS PharmSciTech, 2020, 17;21(5):135

PubMed: 32419073 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):626

PubMed: 32796811 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Theranostics, 2018,

PubMed: 30083255 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )
Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245915 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	M{KyeGZ2dmO2aX;uJGF{e2G7	Ml:2NE4yNTNyIN88US=>	MUm0PEBp		Ml;JbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw>	NHXRT\|QzPjVzM{G3Ni=>
H460	M2XRcmZ2dmO2aX;uJGF{e2G7	NFO2V3ExNjFvM{Cg{txO	MWe0PEBp		MUfpcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	MY[yOlUyOzF5Mh?=
HKESC-2	MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7yNlDDqM7:TR?=	MmnWOFjDqGkEoB?=		MV\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA>	MUeyOlQ4PDZ7Mx?=
CaES-17	MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLRXo4zOMLizszN	MmHDOFjDqGkEoB?=		MmTqd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh	NX7sT2tCOjZ2N{S2PVM>
HKESC-2	NInOUmtCeG:ydH;zbZMhSXO\|YYm=	M2HzWlIxyqEQvF2=	M2rifFQ5yqCqwrC=		NH61XJZz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	NV3nO2x7OjZ2N{S2PVM>
CaES-17	NX;INGtZSXCxcITvd4l{KEG\|c3H5	NYTNNYk1OjEEoN88US=>	NYfHbo8yPDkEoHlCpC=>		NWDPOI9xemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	NFviZoYzPjR5NE[5Ny=>
A549	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWS1MVE3OCEQvF2=	MWS0POKhcMLi	NX3PSW1STE2VTx?=	Mk[yTWM2OD1zNkOuOEDPxE1?	NWXESmVYOjZ2NkS2OFM>
HCC827	NEXicJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrWW2Q2NTF4MDFOwG0>	M3r5UFQ5yqCqwrC=	NG\kfI5FVVOR	NFfIN5hKSzVyPU[5MlIh\|ryP	MlvqNlY1PjR4NEO=
A549	NYX4dXFJSXCxcITvd4l{KEG\|c3H5	MlHGPFAhyrWP	NIiwRXo1QMLiaNMg	NHPMeVFFVVOR	NFyzRXhqdmS3Y3XzJIFxd3C2b4Ppdy=>	M4e4fVI3PDZ2NkSz
HCC827	MYPBdI9xfG:\|aYOgRZN{[Xl?	M{POSlgxKML3TR?=	M4HBW\|Q5yqCqwrC=	MULEUXNQ	NIDuZXFqdmS3Y3XzJIFxd3C2b4Ppdy=>	M1XGN\|I3PDZ2NkSz
SGC-7901/DDP	MnfYSpVv[3Srb36gRZN{[Xl?	NHLWfoYyOMLiwsXN	Mly4NlQhcA>?		NED2bVZqdmirYnn0d{BkgWOub3;4fYdmdmG\|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v	NY\QblVIOjZ2MEe2OVM>
SGC-7901	NIXKVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXvOTFRLOjUEoHlCpC=>		NVz3PIhSUUN3ME2xNVUvODhizszN	MV[yOlQxPzZ3Mx?=
SGC-7901/DDP	NUnRbIVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHfFenUzPMLiaNMg		M4Hy[mlEPTB;M{WuOFUh\|ryP	Mmr5NlY1ODd4NUO=
SGC-7901/DDP	MX7BdI9xfG:\|aYOgRZN{[Xl?	NGjw[lgyOMLiwsXN	NE\QRW8zPCCq		M{nHdolv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4>	NUe3W4xPOjZ2MEe2OVM>
SGC-7901/DDP	NFfrOphHfW6ldHnvckBCe3OjeR?=	NWPKN2NwOTEEoNM1US=>	MX6yOEBp		MW\pcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDQMYdtgWOxcILveIVqdiC2aILveYdpKGKub3PrbY5oKEWSMjygZY5lKGmwYXP0bZZifGmwZzDQT2Eh[W6mIFPSSWLDqA>?	M4rBeFI3PDB5NkWz
SGC-7901/DDP	MnK3SpVv[3Srb36gRZN{[Xl?	NXjTbHlQOTEEoNM1US=>	MnThNlQhcA>?		NYLmTWpE[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv	NH\qcW4zPjRyN{[1Ny=>
H357	NVjBPJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrER5k4NjVxMUCg{txO	MY[0PEBp	NWO1PJJPTE2VTx?=	NWTpWWFQcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>?	M33QdVI3ODB7OEe0
TAF	MonCSpVv[3Srb36gRZN{[Xl?	M4HmfFExyqEEtV2=	MmfPO{Bl		M3\qUIFn\mWldIOgWGFHeyCjZHjld4l3\SCycn;w[ZJ1cWW\|	NHLrUIszPTl6N{GyOy=>
TAF	MV7GeY5kfGmxbjDBd5NigQ>?	MWexNOKhyrWP	Ml7sN\|AuOTJyIH3pci=>		M{TJepBwd3KueTDh[oZm[3S\|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=>	NXTtbnBkOjV7OEexNlc>
TAF	M4TSeWZ2dmO2aX;uJGF{e2G7	MlnmNVDDqML3TR?=	NWX2Wo5sPDhiaB?=		NUj4T2d6cW6lcnXhd4V{KEWJRmKgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;u	NUGyN4dZOjV7OEexNlc>
PANC-1	NHPsdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PsdFIxNzZyL{GwNEDPxE1?	MUeyOE81QC95MjDo		M{\UR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NVW5c4xKOjV7N{OwOlI>
PANC-1	MlHwSpVv[3Srb36gRZN{[Xl?	MnzVNlAwPjBxMUCwJO69VQ>?	NIHGdmwzPCCq		MYXheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	NHjh[ZEzPTl5M{C2Ni=>
HeLa	M3jxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUWyNOKh\|ryPwrC=	NVLzVnpTOjUEoHi=		NGnYO4FmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=	MWKyOVc4ODR{Mx?=
SACC-83	MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjpfJAzOMLizszNxsA>	NVTU[JN1OjUEoHi=		NFHQR\|ZmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=	MXGyOVc4ODR{Mx?=
HeLa	MUHBdI9xfG:\|aYOgRZN{[Xl?	MkXuNlDDqM7:TdMg	MlrCNlTDqGh?		MVTlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz	NEiyUYszPTd5MESyNy=>
SACC-83	NHP0TmlCeG:ydH;zbZMhSXO\|YYm=	MU[yNOKh\|ryPwrC=	MkXiNlTDqGh?		NHzHNohmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{	M2jOO\|I2PzdyNEKz
HeLa	MlHCSpVv[3Srb36gRZN{[Xl?	MVSyNE81OC96MDFOwG0>	NIX0bo0zPMLiaB?=		MoP3eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q>	M3zTW\|I2PzdyNEKz
SACC-83	NUThOGx[TnWwY4Tpc44hSXO\|YYm=	M4LFVlIxNzRyL{iwJO69VQ>?	NIPLPIgzPMLiaB?=		M1:ydJVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV	NG\J[3QzPTd5MESyNy=>
HLCZ01	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3naVVDjiJN4MNMgxtVO	M2fNb\|Q5KGh?	M4XuTmROW09?	NXHtN3VjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NY\2WpRFOjV5MkS4PVk>
HLCZ01	NHr1VWNHfW6ldHnvckBCe3OjeR?=	M4LyXVQxyqEQvF2=	NV6xemVROjRiaB?=	NI\oTHJFVVOR	M322O4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS\|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE>	MkTPNlU4OjR6OUm=
HLCZ01	NYG0[FNoSXCxcITvd4l{KEG\|c3H5	MUe0NOKh\|ryP	NGLEU2EzPCCq	MkfsSG1UVw>?	MWTlcohidmOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCCLRl6t{tE>	MkKzNlU4OjR6OUm=
HLCZ01	NYXvWVc1TnWwY4Tpc44hSXO\|YYm=	NY\OcmxbPDEEoN88US=>	MlrINlQhcA>?	MUPEUXNQ	NWD2ZnpVcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y	NXnoZpJyOjV5MkS4PVk>
MGC803	M{PCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzmNE03OCEQvF2=	MkTnO\|IhcA>?		M2jjNGlEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN	NFjQNlkzPTdyMUO3PC=>
SGC7901	M4LWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG[3TngxNTZyIN88US=>	M1\qTlczKGh?		MkDTTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2=	M1nqSFI2PzBzM{e4
MGC803	M1zKS2Z2dmO2aX;uJGF{e2G7	NHqxU3I1OMLizszN	MkjHPE8yPi9{NDDo		NYDPUnhofXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v	NYfOVo0zOjV5MEGzO\|g>
SGC7901	MnT6SpVv[3Srb36gRZN{[Xl?	NGm0dlI1OMLizszN	NEf1[mE5NzF4L{K0JIg>		NFy5TlR2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44>	MmTNNlU4ODF\|N{i=
MCF-7	NEnFZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXxPFcyNzFyIN88US=>	NHnaeJc4OiCq	M2HBd2ROW09?	MVflcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>?	NETLOJkzPTZ4N{WxNC=>
MDA-MB-231	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEm0fXUyNzFyIN88US=>	MlG0O\|IhcA>?	MWnEUXNQ	M4DlW4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w	NUjMfFZyOjV4Nke1NVA>
MDA-MB-231	M3T5emZ2dmO2aX;uJGF{e2G7	NUnDS3dPOC12MDFCuW0>	MYW0MVI1KGh?		Mn7SbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NWDhNoQxOjV3OEezNlk>
MCF-7	NFyy[m9HfW6ldHnvckBCe3OjeR?=	NHTY[WIxNTRyINM1US=>	MWW0MVI1KGh?		NHTBdVJmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS\|Ih\XiycnXzd4lwdsLi	MXeyOVU5PzN{OR?=
MCF7-MX	NXjJTnJQTnWwY4Tpc44hSXO\|YYm=	M{K0S\|AuPDBiwsXN	M{nCcFQuOjRiaB?=		M3Pnb4VvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB?	MlTWNlU2QDd\|Mkm=
MDA-MB-231	MXnGeY5kfGmxbjDBd5NigQ>?	MkPCNE01OCEEtV2=	MXS0MVI1KGh?		M{W0[JN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?=	NVzGRnd3OjV3OEezNlk>
A2780	MWjGeY5kfGmxbjDBd5NigQ>?	NEfLbJA2NzFyL{G1JO69VQ>?	NEnCbYU1QCCq		Mofj[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MnfDNlU1OjR6OUi=
SKOV3	MWXGeY5kfGmxbjDBd5NigQ>?	MXy1M\|ExNzF3IN88US=>	NG\kOJM1QCCq		NWnlNlFw\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MojLNlU1OjR6OUi=
A2780	MXfGeY5kfGmxbjDBd5NigQ>?	MoPPOU8yOC9zNTFOwG0>	MnzyOFghcA>?		NHvoW2RmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw	M3\ET\|I2PDJ2OEm4
SKOV3	M{fkcWZ2dmO2aX;uJGF{e2G7	NXr3R\|RsPS9zMD:xOUDPxE1?	NF;6ZoE1QCCq		M4XnS4Vt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5?	NH3LTGMzPTR{NEi5PC=>
A2780	NXTwOopwTnWwY4Tpc44hSXO\|YYm=	NVqzS2xXPS9zMD:xOUDPxE1?	M2DiNVQ5KGh?		MV3k[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?	NXr5PYY1OjV2MkS4PVg>
SKOV3	NWHZ[GEyTnWwY4Tpc44hSXO\|YYm=	NV;INphYPS9zMD:xOUDPxE1?	MW[0PEBp		NEHDbnFl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6=	MmDmNlU1OjR6OUi=
A2780	NHrkVWJHfW6ldHnvckBCe3OjeR?=	NXfJRZhPPS9zMD:xOUDPxE1?	MWOxJIg>		NFG3eY1qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFG5VHAzPTR{NEi5PC=>
SKOV3	MlTvSpVv[3Srb36gRZN{[Xl?	NXvBbIt{PS9zMD:xOUDPxE1?	NVe0NGJHOSCq		NI\l[lhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MkjGNlU1OjR6OUi=
HCT-15	NGC1VWJHfW6ldHnvckBCe3OjeR?=	NYnnOml4OTBvNUCg{txO	M17DNVYuOzZiaB?=		MWLpcoR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	NFf0fFAzPTJzOECyPC=>
HT-29	MXHGeY5kfGmxbjDBd5NigQ>?	M1m1bFExNTVyIN88US=>	M1TUZVYuOzZiaB?=		MVHpcoR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	NWPLfos3OjV{MUiwNlg>
HSC3	MorCR4VtdCCYaXHibYxqfHliQYPzZZk>	NG\H[I4x6oDVNECg{txO	M1izUVQ5KGh?		MXjJR\|UxRTJ3LkZCtVEvPzhyIN88US=>	MlfFNlUyQTh5OEm=
HSC3	M1ns[2Fxd3C2b4Ppd{BCe3OjeR?=	MUKyOUDPxE1?	NGS4PFE1QCCq		MY\pcoR2[2W\|IHHwc5B1d3Orcx?=	MlXINlUyQTh5OEm=
HSC3	M4LaXmZ2dmO2aX;uJGF{e2G7	NGHpcIEzPSEQvF2=	MUm0PEBp		NWTSeJJN\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?=	M2PubFI2OTl6N{i5
HSC3	NV6yO3h5TnWwY4Tpc44hSXO\|YYm=	MU[yOUDPxE1?	M2DTOVQ5KGh?		NFzmcmNqdmirYnn0d{BJW0N\|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ>	MYWyOVE6QDd6OR?=
HSC3	M4i1dWZ2dmO2aX;uJGF{e2G7	NGKzeJkzPSEQvF2=	NEjLd3g4OiCq		Mke4[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg	MmfENlUyQTh5OEm=
201T	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUHmVmpIPzJiaB?=	NGT0cG5FVVOR	M2DPcWlEPTB;NEiuOkDDvU1?	M4Dk[VI2ODV5OUSx
273T	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXj0eXk3PzJiaB?=	M3rwbGROW09?	M3i3fmlEPTB;OECuOUDDvU1?	NHXhcHYzPTB3N{m0NS=>
Hep-2	NHLrOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\JWYZ1OzBxNUCvNVAxKM7:TR?=	MX[xNk8zPC9\|Nj:0PEBp	NG[2S5RFVVOR	NWXNeINZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MoDCNlQ6QTh3NkS=
Hep-2	MV3BdI9xfG:\|aYOgRZN{[Xl?	NXzqdGxwPTBizszN	NFL4OXcxNTR6IHi=	NYjBO\|BmTE2VTx?=	M1zvVYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MYeyOFk6QDV4NB?=
Hep-2	MXzGeY5kfGmxbjDBd5NigQ>?	NHzu[5c2OCEQvF2=	M4HBOlAuPDhiaB?=	NUL0RnhYTE2VTx?=	NVi5fZpCemWmdXPld{B1cGVidHXsc41memG\|ZTDhZ5Rqfmm2eTDndoFlfWGubIm=	Mn;UNlQ6QTh3NkS=
Hep-2	NE\md5dHfW6ldHnvckBCe3OjeR?=	NYTjT4RQPTBizszN	M1\lSVAuPDhiaB?=	Mlm3SG1UVw>?	NYjWfJFt\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR?	MlrVNlQ6QTh3NkS=
SGC-7901	NWLFRodyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWqxNE82OC9zMECg{txO	NWDz[GVzOjRxNEivO\|IhcA>?	MoTsSG1UVw>?	Ml3vbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MU[yOFk6Ojl3OB?=
MKN-45	NF:2RXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPlXJcyOC93MD:xNFAh\|ryP	M4rtdFI1NzR6L{eyJIg>	MWnEUXNQ	MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M3jMV\|I1QTl{OUW4
SGC-7901	MnLJSpVv[3Srb36gRZN{[Xl?	MXixNE82OC9zMECg{txO	M4DyR\|Q5KGh?	NFf5WmpFVVOR	NHHDNZBld3ewcnXneYxifGW\|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy\|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M{CzXFI1QTl{OUW4
MKN-45	MkLLSpVv[3Srb36gRZN{[Xl?	NIrqNmIyOC93MD:xNFAh\|ryP	M3fKeFQ5KGh?	NGjnenRFVVOR	M3\5cYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NWjqVHpmOjR7OUK5OVg>
C666-1	NELqO4ZEgXSxdH;4bYNqfHliQYPzZZk>	MViyNE05OCEQvF2=	NF7DcnYzPCCq		NVnMRXk4\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	M2TYN\|I1QDV2OEO4
CNE-1	NVS4co1GS3m2b4TvfIlkcXS7IFHzd4F6	MknpNlAuQDBizszN	MVSyOEBp		M4rpfIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	M1P6SFI1QDV2OEO4
CNE-2	MlztR5l1d3SxeHnjbZR6KEG\|c3H5	NFrMeWEzOC16MDFOwG0>	MoXCNlQhcA>?		MWnk[YNz\WG\|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg	MViyOFg2PDh\|OB?=
C666-1	NGfXe\|dEgXSxdH;4bYNqfHliQYPzZZk>	MYS2NEDPxE1?	MnjmO{Bl		NV7Td3k5\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	Mn\pNlQ5PTR6M{i=
CNE-1	NHfmOpFEgXSxdH;4bYNqfHliQYPzZZk>	Ml7VOlAh\|ryP	M1m5VVch\A>?		NWPZR\|B3\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	MVyyOFg2PDh\|OB?=
SNU-1041	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vOZlAuPDBizszN	NVe1UFlZPDhiaB?=		MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M3zRXVI1Pjl{N{Cz
SNU-1041	MoXxSpVv[3Srb36gRZN{[Xl?	NXLMSXFFOjBxM{Cg{txO	NUnDcpBvPCCq		NEPLXoZqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	M1XTPFI1Pjl{N{Cz
SNU-1041	MX7GeY5kfGmxbjDBd5NigQ>?	Mo\QNE01OCEQvF2=	NYDRUHBiPCCq		MWP1dE1z\We3bHH0[ZMhS0iRUNMgZYZ1\XJidILlZZRu\W62IIfpeIghcGmpaDDjc45k\W62cnH0bY9vew>?	MnjuNlQ3QTJ5MEO=
SGC-7901	MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXnfWhnPTBvMUK1JO69VQ>?	NGP0fXMzPC92OD:3NkBp		MkPrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NHP1W3ozPDZ5NkO5OC=>
SGC-7901	MYDBdI9xfG:\|aYOgRZN{[Xl?	NHvHSJoyODBizszN	M3LF[VczKGh?		MYfpcoR2[2W\|IHHwc5B1d3Orcx?=	MVuyOFY4PjN7NB?=
SGC-7901	MojsSpVv[3Srb36gRZN{[Xl?	NEX1VHo4PS9zMECvNVI2KM7:TR?=	M1vyWVI1NzR6L{eyJIg>		MXPpcoNz\WG\|ZYOgZ4F{eGG\|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?=	Ml6zNlQ3PzZ\|OUS=
LMeC	MXLGeY5kfGmxbjDBd5NigQ>?	MlHzNlAwPTBizszN	Mn\zOFghcA>?		NI\ZNYxl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?=	NYnpVYkzOjR4NU[3OFY>
CMeC-1	NF\0ZmdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MY[yNE82OCEQvF2=	M2HvR\|Q5KGh?		Ml\ZbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NUfoN2F2OjR4NU[3OFY>
LMeC	M1iyU2NmdGxiVnnhZoltcXS7IFHzd4F6	NInqN\|MzOC93MDFOwG0>	M1:zdVQ5KGh?		NWLHNmlvcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MonPNlQ3PTZ5NE[=
CMeC-1	Ml\KSpVv[3Srb36gRZN{[Xl?	Mo\qNlAwPTBizszN	MWW0PEBp		MVfpcoR2[2W\|IFexMXMh[XK{ZYP0	MlTONlQ3PTZ5NE[=
LMeC	MlLISpVv[3Srb36gRZN{[Xl?	NVzJWWdWOjBxNUCg{txO	M4HNV\|Q5KGh?		NWjifmlDcW6mdXPld{BIOS2VIHHydoV{fA>?	M2XrcFI1PjV4N{S2
CMeC-1	NV;2WHBbTnWwY4Tpc44hSXO\|YYm=	NVjWeWxOOjBxNUCg{txO	M{DycVQ5KGh?		NVXPVIdH\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NXLaOmNJOjR4NU[3OFY>
LMeC	MWDGeY5kfGmxbjDBd5NigQ>?	MWSyNE82OCEQvF2=	NHvXems1QCCq		M4HPXIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3\ORVI1PjV4N{S2
CMeC-1	M3;2c2Z2dmO2aX;uJGF{e2G7	NFfzfXgzOC93MDFOwG0>	M{S5NlQ5KGh?		MUnpcoR2[2W\|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u	MYOyOFY2Pjd2Nh?=
LMeC	MkHYSpVv[3Srb36gRZN{[Xl?	NVfpcWI5OjBxNUCg{txO	NF[y[Wg1QCCq		NVr2UXM4cW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>?	MmjZNlQ3PTZ5NE[=
OVCAR-3	M3G1eGNmdGxiVnnhZoltcXS7IFHzd4F6	NGroXJkyOCEEtV2=	M33FRVEhcA>?		MnnO[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=>	MWeyOFUzODJ{Nx?=
OVCAR-3	NYflfHpRSXCxcITvd4l{KEG\|c3H5	NYHmcFlIOTBiwsXN	NHfLZ4cyKGh?		NGDUNJpxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB?	M2nyc\|I1PTJyMkK3
OVCAR-3	MXPGeY5kfGmxbjDBd5NigQ>?	NHHGfI0yOCEEtV2=	NFHKOYcyKGh?		NF3SZnVmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=>	NWj2RZdbOjR3MkCyNlc>
OVCAR-3	NF7DdFBHfW6ldHnvckBCe3OjeR?=	M{H1e\|ExKML3TR?=	MWOxJIg>		M2LWcYRwf25vcnXneYxifGW\|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=>	M1vtTFI1PTJyMkK3
OVCAR-3	MontSpVv[3Srb36gRZN{[Xl?	M1zOWFExKML3TR?=	M{XrdVEhcA>?		MX7pcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=>	MYKyOFUzODJ{Nx?=
CF33	MmLLSpVv[3Srb36gRZN{[Xl?	MljmNVAxKM7:TR?=	MWOyOEBp		MVjpcoR2[2W\|IHTve45z\We3bHH0bY9vKG:oIFPPXE0zKHC{b4TlbY4h\XiycnXzd4lwdg>?	MlrTNlQ2ODN5OEK=
CF33	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLnNVAuOTByIN88US=>	MWGwMVQh\A>?		NUS1V5BycW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3rqZVI1PTB\|N{iy
CF33	MY\GeY5kfGmxbjDBd5NigQ>?	NIHzN5IyOC1zMECg{txO	NGLRb3Y1NTJ2IHi=		NYTvUmJs\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2	MWCyOFUxOzd6Mh?=
LNCaP	NGX5PI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULUd49XOi93L{GwJO69VQ>?	NX7NOZl{QTZiaB?=		NHu1OVdqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu	NFO5fmIzPDJ7Nkm3PC=>
LNCaP	NGfleHFCeG:ydH;zbZMhSXO\|YYm=	M4L6eVIwPS9zMDFOwG0>	NUmyO5NPQTZiaB?=		NHj0em9qdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	MX6yOFI6Pjl5OB?=
PC-3	NXLKfnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWwMVUxKM7:TR?=	NUXY[3dYPDkkgJno		MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MWCyOFEzPzh6Mh?=
PC-3	M3fRdmNmdGxiVnnhZoltcXS7IFHzd4F6	NUi1ZnlNOC1zMECg{txO	MlHpO\|IhcA>?		M3rxZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M4f2NlI1OTJ5OEiy

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Water	Insoluble
	Ethanol	'33 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SC 58635
Smiles	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526197	Enrolling by invitation	Drug: ALXN1840\|Drug: Celecoxib	Wilson Disease	Alexion Pharmaceuticals	July 8 2020	Phase 1
NCT04447261	Recruiting	Drug: BI 1356225\|Drug: Placebo	Obesity	Boehringer Ingelheim	June 30 2020	Phase 1
NCT03896113	Recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	November 13 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin (Acetylsalicylic acid) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Rofecoxib

Rofecoxib (MK-0966) is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib